ГоловнаArchive of numbers2015Volume 23, issue 3(84)Cardiovascular risk factors evaluation in patients with epilepsy
Title of the article Cardiovascular risk factors evaluation in patients with epilepsy
Authors Grymailo Valeriia
In the section DIAGNOSTICS AND THERAPY OF NEUROLOGICAL DISORDERS
Year 2015 Issue Volume 23, issue 3(84) Pages 39-42
Type of article Scientific article Index UDK 616.853-06:616.12-073.7-076 Index BBK -
Abstract World literature data and own observations of 50 patients with epilepsy who underwent cardiovascular risk factors assessment are represented in the article. Patients doesn’t complain of any symptoms, specifi c to cardiac pathology. Patients with diagnosed cardiovascular pathology were excluded of the research. We have revealed that valproates and carbamazepine are associated with the development of dyslipidemia, the severity of which depends on the dose and duration of the drugs administration; carbamazepine usage is associated with an increased risk of cardiac rhythm and conductance disturbances. It is important for patients taking valproates to determine the body mass index, index of abdominal obesity, to control the blood pressure, as well as determining of the intima-media complex thickness for the earliest detection of cardiovascular risk factors, such as the development of abdominal obesity, high blood pressure, atherogenesis and their timely correction.
Key words epilepsy, cardiovascular risk, cardiac disorders.
Access to full text version of the article pdf download
Bibliography 1. Карлов В. А. Эпилепсия у детей и взрослых, женщин и мужчин : руководство для врачей / В. А. Карлов. — М.: Медицина, 2010. — 720 с. 2. Shorvon S. The treatment of epilepsy / S. Shorvon. — Wiley- Blackwell, Oxford, 2009. — P. 1200. 3. So E. L. What is known about the mechanisms underlying SUDEP? / E. L. So // Epilepsia. — 2008 Dec; 49 Suppl 9: 93—8. 4. Philippe R. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study / Philippe R., Lina N., Samden D. // The Lancet Neurology. — 2013, October. — Vol. 12. — Issue 10. — P. 966—977. 5. Tomson Torbjörn. Sudden unexpected death in epilepsy: current knowledge and future directions / Torbjörn Tomson, Lina Nashef, Philippe Ryvlin // The Lancet Neurology. — 2008, November. — Vol. 7, Issue 11. — P. 1021—1031. 6. Jonas B. Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study / B. Jonas, Z. Steen // Pharmacoepidemiology and Drug Safety (Impact Factor: 3.17). 07/2011; 20(9): 964—71. DOI: 10.1002/pds.2186 7. Lopinto-Khoury C. Antiepileptic drugs and markers of vascular risk / C. Lopinto-Khoury, S. Mintzer // Current Treatment Options in Neurology. — 07/2010; 12(4): 300—8. 8. Metabolic and endocrine effects of valproic acid chronic treatment / [Vincenzo Belcastro, Claudia D'Egidio, Pasquale Striano, Alberto Verrotti] // Epilepsy Research. — 09/2013; 107(1—2). 9. Atherogenic consequence of antiepileptic drugs: a study of intima-media thickness / [Mehrpour M., Shojaie M., Zamani B. et al.] // Neurol Sci. — 2014 Feb; 35(2): 253—7. 10. Lipid Profile and Carotid Intima-Media Thickness as Predictors for Early Atherosclerosis in Epileptic Children / [Enas Mahmoud Hasan, Osama Mahmoud Momtaz, Laila El Morsi Aboul-Fotoh et al.] // Egyptian Journal of Neurology, Psychiatry & Neurosurgery. — 01/2013; 50 (1): 55.